Hilda Petrs-Silva

Prof. Hilda Petrs-Silva

Instituto de Biofísica Carlos Chagas Filho, UFRJ, RJ, Brazil
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva
ADAstra Dinculescu
Astra Dinculescu
QLQiuhong Li
Qiuhong Li
SMSeok-Hong Min
Seok-Hong Min
VCVince Chiodo
Vince Chiodo
WHWilliam W Hauswirth
William W Hauswirth
Vectors derived from adeno-associated viruses (AAVs) have become important gene delivery tools for the treatment of many inherited ocular diseases in well-characterized animal models. Previous studies have determined that the viral capsid plays an essential role in the cellular tropism and efficiency of transgene expression. Recently, it was shown that phosphorylation of surface-exposed tyrosine residues from AAV2 capsid targets the viral particles for ubiquitination and proteasome- mediated degradation, and mutations of these tyrosine residues lead to highly efficient vector transduction in vitro and in vivo. Because the tyrosine residues are highly conserved in other AAV serotypes, in this study we evaluated the intraocular transduction characteristics of vectors containing point mutations in surface- exposed capsid tyrosine residues in AAV serotypes 2, 8, and 9. Several of these novel AAV mutants were found to display a strong and widespread transgene expression in many retinal cells after subretinal or intravitreal delivery compared with their wild-type counterparts. For the first time, we show efficient transduction of the ganglion cell layer by AAV serotype 8 or 9 mutant vectors, thus providing additional tools besides AAV2 for targeting these cells. These enhanced AAV vectors have a great potential for future therapeutic applications for retinal degenerations and ocular neovascular diseases.

1 February 2011 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva
Astra DinculescuAstra Dinculescu
Astra Dinculescu
QLQiuhong Li
Qiuhong Li
Wen-Tao DengWen-Tao Deng
Wen-Tao Deng
JPJi-Jing Pang
Ji-Jing Pang
WHWilliam W Hauswirth
William W Hauswirth
Vectors based on adeno-associated virus serotype 2 (AAV2) have been used extensively in many gene-delivery applications, including several successful clinical trials for one type of Leber congenital amaurosis in the retina. Many studies have focused on improving AAV2 transduction efficiency and cellular specificity by genetically engineering its capsid. We have previously shown that vectors-containing single-point mutations of capsid surface tyrosines in serotypes AAV2, AAV8, and AAV9 displayed significantly increased transduction efficiency in the retina compared with their wild-type counterparts. In the present study, we evaluated the transduction characteristics of AAV2 vectors containing combinations of multiple tyrosine to phenylalanine mutations in seven highly conserved surface-exposed capsid tyrosine residues following subretinal or intravitreal delivery in adult mice. The multiply mutated vectors exhibited different in vivo transduction properties, with some having a unique ability of transgene expression in all retinal layers. Such novel vectors may be useful in developing valuable new therapeutic strategies for the treatment of many genetic diseases.

1 May 2020 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
GNGabriel Nascimento-Dos-Santos
Gabriel Nascimento-Dos-Santos
EFEduardo Ferreira
Eduardo Ferreira
RLRafael Lani
Rafael Lani
CFCaroline Coelho de Faria
Caroline Coelho de Faria
VAVictor Guedes Araújo
Victor Guedes Araújo
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva

1 December 2013 in Clinical Ophthalmology
Verified
Journal Article
Open access
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva
RLRafael Linden
Rafael Linden
Peer reviewed article authored by (Petrs-Silva H, Linden R). Read article or submit your manuscript for publishing.

Verified
Journal Article
Open access
PDF file
MDMariana Santana Dias
Mariana Santana Dias
XLXiaoyue Luo
Xiaoyue Luo
VRVinicius Toledo Ribas
Vinicius Toledo Ribas
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva
JKJan Christoph Koch
Jan Christoph Koch
Glaucoma is a neurodegenerative disease that affects the retinal ganglion cells (RGCs) and leads to progressive vision loss. The first pathological signs can be seen at the optic nerve head (ONH), the structure where RGC axons leave the retina to compose the optic nerve. Besides damage of the axonal cytoskeleton, axonal transport deficits at the ONH have been described as an important feature of glaucoma. Axonal transport is essential for proper neuronal function, including transport of organelles, synaptic components, vesicles, and neurotrophic factors. Impairment of axonal transport has been related to several neurodegenerative conditions. Studies on axonal transport in glaucoma include analysis in different animal models and in humans, and indicate that its failure happens mainly in the ONH and early in disease progression, preceding axonal and somal degeneration. Thus, a better understanding of the role of axonal transport in glaucoma is not only pivotal to decipher disease mechanisms but could also enable early therapies that might prevent irreversible neuronal damage at an early time point. In this review we present the current evidence of axonal transport impairment in glaucomatous neurodegeneration and summarize the methods employed to evaluate transport in this disease.

20 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
GNGabriel Nascimento-Dos-Santos
Gabriel Nascimento-Dos-Santos
EFEduardo Ferreira
Eduardo Ferreira
RLRafael Linden
Rafael Linden
AGAntonio Galina
Antonio Galina
Hilda Petrs-SilvaHilda Petrs-Silva
Hilda Petrs-Silva
Mitochondria are key players of aerobic respiration and the production of adenosine triphosphate and constitute the energetic core of eukaryotic cells. Furthermore, cells rely upon mitochondria homeostasis, the disruption of which is reported in pathological processes such as liver hepatotoxicity, cancer, muscular dystrophy, chronic inflammation, as well as in neurological conditions including Alzheimer’s disease, schizophrenia, depression, ischemia and glaucoma. In addition to the well-known spontaneous cell-to-cell transfer of mitochondria, a therapeutic potential of the transplant of isolated, metabolically active mitochondria has been demonstrated in several in vitro and in vivo experimental models of disease. This review explores the striking outcomes achieved by mitotherapy thus far, and the most relevant underlying data regarding isolated mitochondria transplantation, including mechanisms of mitochondria intake, the balance between administration and therapy effectiveness, the relevance of mitochondrial source and purity and the mechanisms by which mitotherapy is gaining ground as a promising therapeutic approach.